Allogene Therapeutics, Inc. Common Stock

ALLO XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

710M

Short interest (May 15)

12.3%

Net Short (Jun 03 ): 0.3%

Borrow Fee

0.41%

↓ 30.8%

Available Shares

10M

↑ 0.1%

Price Chart

Company Overview

Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001737287

Asset Type: CS

Market Data

Market Cap: $707,566,850

Employees: 152

Status: Active

Short Interest

Current Borrow Fee 0.41%

Range: 0.25% - 0.41%

Available Shares 10M

Range: 6.3M - 10M

Recent Changes

Fee Change: ↓ 0.0%

Available Change: ↑ 2.1%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime